Madrigal Pharmaceuticals (MDGL) announced an exclusive global license agreement with Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals for six preclinical small interfering RNA programs. siRNAs offer a precision approach to gene silencing in MASH by selectively reducing the production of disease-driving proteins.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals price target lowered to $570 from $595 at BofA
- Madrigal Gains Expanded Patent Control Over Rezdiffra With Roche
- Madrigal Pharmaceuticals initiated with an Overweight at Barclays
- Madrigal, Clene, Cencora, Sequans, Amicus: Insider Moves Exposed
- Madrigal Pharmaceuticals price target raised to $745 from $527 at Citizens